We serve Chemical Name:tert-butyl (2S)-2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylate CAS:426844-50-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:tert-butyl (2S)-2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylate
CAS.NO:426844-50-0
Synonyms:BOC-4,4-DIFLUORO-L-PROLINAMIDE;N-Boc-4,4-difluoropyrrolidine-L-proline amide;2S-Carbamoyl-4,4-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester
Molecular Formula:C10H16F2N2O3
Molecular Weight:250.24200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:372.8ºC at 760 mmHg
Density:1.26g/cm3
Index of Refraction:1.478
PSA:72.63000
Exact Mass:250.11300
LogP:1.75460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like BOC-4,4-DIFLUORO-L-PROLINAMIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2S-Carbamoyl-4,4-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2S-Carbamoyl-4,4-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester Use and application,2S-Carbamoyl-4,4-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester technical grade,usp/ep/jp grade.
Related News: Both were randomised, double-blinded, placebo-controlled trials in patients with moderate to severe autoantibody-positive SLE who were receiving standard therapy. 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethylpyrrolidin-1-yl)-4-oxahept-1-yl]-N-(prop-1-yl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine manufacturers This so-called ‘green chemistry’ is much safer than metal-catalyzed approaches and can save vast quantities of reagents, consumables, organic solvents, and energy over the lifetime of a project to dramatically reduce waste and environmental burden. 3-chloro-N-(1-(2-fluorophenyl)-2-oxo-2-((4-(2-oxopiperidin-1-yl)phenyl)amino)ethyl)-1H-indole-6-carboxamide suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 2′-((4′-fluoro-[1,1′-biphenyl]-4-yl)methyl)-5′-methyl-1’H,8’H-spiro[cyclopentane-1,7′-imidazo[2,1-b]purin]-4′(5’H)-one hydrochloride vendor & factory.
